Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market

Published Aug 14, 2026, 2:30 PM

A new Japanese patent allowance follows a recent such US patent grant, strengthens protection around the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC, extending the company’s intellectual property footprint into one of the world’s largest cartilage-repair markets.
The process delivers a 5-fold increase in yield along with simplified production and commercial scalability, the manufacturing economics needed to make an off-the-shelf cartilage product commercially viable at scale.
The milestone lands as Regentis advances European commercialization and passes the halfway mark in enrollment for its pivotal U.S. trial.

Aging populations are pushing joint disease higher on the orthopedic agenda, with cartilage damage representing one of the field’s largest unmet needs. Current treatments have demonstrated clinical utility, but they remain difficult to deliver efficiently and economically on scale. That gap is where off-the-shelf therapies can deliver high value, and where manufacturing know-how and intellectual property becomes just as important as clinical performance.

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel for knee cartilage repair delivered in a single procedure of about 10 minutes, with no cell harvesting or laboratory processing. On July 20, the company strengthened…